Malaria related HIV morbidity and death is a concern in sub-Saharan Africa. Understanding the epidemiology of malaria among people living with HIV is vital for adequate intervention. We conducted a systematic review and meta-analysis to estimate the prevalence of malaria in HIV patients in sub-Saharan Africa. We searched PubMed, AJOL, Web of Science and Google Scholar databases. The overall pooled prevalence and pooled Odds Ratio (OR) with their 95% Confidence Intervals (CI) were estimated using the random-effects model and potential causes of heterogeneity in prevalence estimates were investigated using subgroup and meta-regression analysis. 58 studies, including 23,911 HIV patients, were identified between January 1990 and October 2020. The overall pooled prevalence of malaria in HIV patients was 22.7% (95% CI 18.0; 28.1). The Prevalence of malaria among HIV/AIDS patients was 33.1%, 30.2%, 15.3%, and 12.6% in Southern, Western, Central, and Eastern regions of SSA respectively. Prevalence of malaria in the central and western was higher [26.7% (95% CI 20.6; 33.9)] than 13.6% reported in the southern and eastern regions (95% CI 8.8; 20.5). There was a significant decrease in malaria prevalence among HIV/AIDS patients in the Eastern and Southern SSA regions from 21.9% (95% CI 15.5; 30.0) in the 2000-2010 period to 9.7% (95% CI 5.5-16.4) in the post-2010 period compared to the central and western regions HIV infected patients with low CD4 + T cell count (CD4 < 200 cells/mm3) were 2.19 times more likely to become infected with malaria than those with high CD4 + T cell count (CD4 ≥ 200 cells/mm3) (pooled odds ratio (POR): 2.19 (95%CI 1.20;3.98), while patients on antiretroviral therapy (POR): 0.37 (0.23; 0.59), and in WHO clinical stages I and II (POR): 0.64 (0.28; 1.46), had a lower odds of been infected with malaria. Our review suggests that due consideration should be given to malaria among HIV/AIDS patients in SSA. In particular, the assessment and improvement of preventive measures for malaria/HIV co-infection in high-prevalence regions is important. For the treatment of both diseases, prophylaxis with cotrimoxazole and antiretroviral therapy should also be encouraged.

在撒哈拉以南非洲，与疟疾有关的艾滋病毒发病率和死亡率令人担忧。了解艾滋病毒携带者中的疟疾流行病学对于适当干预至关重要。我们进行了系统的回顾和荟萃分析，以评估撒哈拉以南非洲艾滋病毒患者的疟疾患病率。我们搜索了PubMed，AJOL，Web of Science和Google Scholar数据库。使用随机效应模型估算总体合并患病率和合并赔率（OR）及其95％置信区间（CI），并使用亚组和荟萃回归分析调查患病率估计中异质性的潜在原因。在1990年1月至2020年10月之间，共进行了58项研究，包括23,911名HIV患者。在HIV患者中，疟疾的总体合并患病率为22.7％（95％CI 18.0； 28.1）。在南部非洲，南部，西部，中部和东部地区，艾滋病毒/艾滋病患者的疟疾患病率分别为33.1％，30.2％，15.3％和12.6％。中部和西部的疟疾流行率较高[26.7％（95％CI 20.6; 33.9）]，高于南部和东部地区报告的13.6％（95％CI 8.8; 20.5）。东部和南部SSA地区的艾滋病毒/艾滋病患者的疟疾流行率从2000-2010年的21.9％（95％CI 15.5; 30.0）显着下降到2000-2010年的9.7％（95％CI 5.5-16.4）。与中部和西部地区相比，2010年以后的时期CD4 + T细胞计数低（CD4 <200细胞/ mm3）的HIV感染患者被疟疾感染的可能性是CD4 + T细胞计数高的患者（CD4）的2.19倍≥200个/ mm3）（池赔率（POR）：2.19（95％CI 1.20; 3.98），而接受抗逆转录病毒疗法（POR）的患者：0.37（0.23; 0.59），并且在WHO的I和II期临床阶段（POR）：0.64（0.28; 1.46），感染疟疾的几率较低。我们的评论表明，在SSA中，应适当考虑艾滋病毒/艾滋病患者中的疟疾。特别是，评估和改善高流行地区的疟疾/ HIV合并感染预防措施非常重要。对于两种疾病的治疗，也应鼓励使用考特莫唑预防和抗逆转录病毒治疗。在高流行地区评估和改善预防疟疾/ HIV合并感染的预防措施非常重要。对于两种疾病的治疗，也应鼓励使用考特莫唑预防和抗逆转录病毒治疗。在高流行地区评估和改善预防疟疾/ HIV合并感染的预防措施非常重要。对于两种疾病的治疗，也应鼓励使用考特莫唑预防和抗逆转录病毒治疗。